Department of Medical Oncology for Melanoma and Sarcoma
Peking University Cancer Hospital, Beijing
黑色素瘤与肉瘤内科 · Medical Oncology
Established in 2005, this department specializes in the medical management of malignant melanoma, other skin cancers, and soft tissue sarcomas. It integrates clinical care with research through a dedicated translational laboratory. The team focuses on immunotherapy, resistance mechanisms, anti-angiogenesis, and targeted gene therapy. As the lead unit for Chinese melanoma treatment guidelines, the department conducts extensive clinical trials. It has contributed to the approval of several new drugs in China, including vemurafenib, dabrafenib/trametinib, and pembrolizumab. The department also helps shape international standards, with findings presented at major conferences such as ASCO and ESMO.
What the department treats
- Medical treatment for malignant melanoma and skin cancers
- Management of soft tissue sarcomas
- Immunotherapy and targeted gene therapy
- Participation in clinical trials and investigator-initiated studies
- Treatment strategies for drug resistance
- Anti-angiogenic therapy
Key facts
- The department was founded in 2005.
- Annual outpatient volume exceeds 30,000 visits, with over 8,000 patients admitted.
- The team includes 10 staff physicians, all holding doctoral degrees.
As described by the hospital.
Team
7 doctors listed.
We are an independent coordination service, not part of this hospital. Team data comes from public doctor-listing platforms; publication counts come from PubMed, matched by full name and affiliation, and doctors with very common names are checked by hand before their papers are shown. How we build this directory.
Not sure which specialist is right?
Send your records. We find a specialist in the right field to review your case and write a treatment plan with a cost estimate.
Get a specialist opinion